The growth of the worldwide disease-modifying antirheumatic drug (DMARD) market is anticipated to be driven by rising product introductions for the treatment of psoriasis and rheumatoid arthritis over the forecast period. For instance, the launch of RediTrex injectable was announced by Cumberland Pharmaceuticals Inc., a specialised pharmaceutical firm in the United States, in November 2020. A new brand of pre-filled syringes called RediTrex was created with the goal of making it simple to administer methotrexate subcutaneously to those with psoriasis and rheumatoid arthritis.
The Global Disease-Modifying Antirheumatic Drug (DMARD) Market size is estimated to be valued at US$ 20,671.1 million in 2022 and is expected to exhibit a CAGR of 3.5% between 2022 and 2030.
Leading Companies in the Disease-Modifying Antirheumatic Drug Industry:
1. Sanofi: Therapeutics developer and distributor focusing on patient requirements. The company sells diabetic and cancer medications, as well as consumer healthcare items, animal health products, and human immunisations. Founded 1973. Headquarters are in Paris, France. Sanofi will purchase Provention Bio, bringing TZIELD, the first disease-modifying medication for the postponement of Stage 3 type 1 diabetes (T1D), to its portfolio
2. Pfizer Inc.: Built in 1848. One of the biggest pharmaceutical companies in the world, Pfizer with yearly sales of around $50 billion (excluding COVID-19 product sales). The company used to sell a wide variety of chemicals and healthcare items, but today the majority of its sales come from prescription medications and vaccinations. United States headquarters. Today, Truveta and Pfizer established a collaborative partnership to give ongoing safety insights based on scalable, verified real-world data.
3. Johnson & Johnson: Johnson & Johnson Development - JJDC - was a venture capital fund run by Johnson & Johnson Innovation. The fund is based in New Brunswick, New Jersey, and it makes investments in the United States. It focused on healthcare devices and supplies, pharmaceuticals and biotechnology, and life science. The company was founded in 1978. In 1978, the headquarters were established. Johnson & Johnson's Janssen Pharmaceutical Companies announced in 2020 that it will expand its existing collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, to seek treatment solutions for COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.
4. AbbVie Inc: Pharmaceutical business AbbVie has a significant presence in oncology and immunology. Humira, the company's best-selling medication, accounts for about half of its current earnings. Early in 2013, the company was separated from Abbott. Established in 2012. American headquarters in North Chicago.
5. Eli Lilly & Company: Eli Lilly is a pharmaceutical company with a focus on immunology, cancer, cardiometabolic disease, and neuroscience. Verzenio for cancer, Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes, Taltz, and Olumiant for immunology are some of Lilly's most important pharmaceuticals. Built in 1875. U.S. headquarters are in Indianapolis
6. Amgen Inc: Amgen is a pioneer in biotechnology-based human medicines with a track record in supportive care for cancer patients and renal disease. Established in 1980. United States headquarters. An agreement for a multi-target, multi-modality research collaboration has been announced by Amgen and Generate Biomedicines.
Definition: Disease-modifying antirheumatic drugs (DMARDs) are a class of drugs indicated for the treatment of several inflammatory arthritides, including rheumatoid arthritis (RA), as well as for the management of other connective tissue diseases and some cancers.
